Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Cell Rep ; 34(4): 108667, 2021 01 26.
Article in English | MEDLINE | ID: mdl-33503436

ABSTRACT

After spinal cord injury (SCI), normally innocuous visceral or somatic stimuli can trigger uncontrolled reflex activation of sympathetic circuitry, causing pathological dysautonomia. We show that remarkable structural remodeling and plasticity occur within spinal autonomic circuitry, creating abnormal sympathetic reflexes that promote dysautonomia. However, when mice are treated early after SCI with human-equivalent doses of the US Food and Drug Administration (FDA)-approved drug gabapentin (GBP), it is possible to block multi-segmental excitatory synaptogenesis and abolish sprouting of autonomic neurons that innervate immune organs and sensory afferents that trigger pain and autonomic dysreflexia (AD). This "prophylactic GBP" regimen decreases the frequency and severity of AD and protects against SCI-induced immune suppression. These benefits persist even 1 month after stopping treatment. GBP could be repurposed to prevent dysautonomia in at-risk individuals with high-level SCI.


Subject(s)
Autonomic Dysreflexia/therapy , Calcium Channel Blockers/therapeutic use , Excitatory Amino Acid Antagonists/therapeutic use , Gabapentin/therapeutic use , Spinal Cord Injuries/therapy , Animals , Autonomic Dysreflexia/pathology , Calcium Channel Blockers/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Gabapentin/pharmacology , Humans , Male , Mice , Spinal Cord Injuries/pathology
SELECTION OF CITATIONS
SEARCH DETAIL